Astellas Pharma Inc. and Pfizer Inc. have announced positive results from their Pivotal Phase 3 EV-303 Clinical Trial for PADCEV. In a separate development, Astellas confirmed their Phase 2 Gleam Trial failed to meet primary endpoint for overall survival in patients with metastatic pancreatic cancer. The company is looking to the future with leadership training and a focus on transformative cancer care. Astellas is also set to present new data on IZERVAY™ in geographic atrophy at the AAO 2025 Annual Meeting, and has entered an exclusive licensing agreement with Evopoint Biosciences. Significant management changes have been announced alongside the company's shift towards Azure, closing a total of 6 data centers worldwide. Despite some challenges such as the Gleam trial, Astellas has seen positive financial performance with recent earnings surpassing expectations. The company's strategic approach includes the creation of innovative partnerships and overall, remains dedicated to advancing the future of biotech.
Astellas Pharma Inc. News Analytics from Wed, 20 Nov 2024 08:00:00 GMT to Sat, 18 Oct 2025 15:35:26 GMT -
Rating 6
- Innovation 5
- Information 8
- Rumor -2
